We are live on ! Find out more
DRMA icon

Dermata Therapeutics
DRMA

6 hedge funds and large institutions have $185K invested in Dermata Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more capital invested

Capital invested by funds: $110K → $185K (+$74.7K)

5.36% more ownership

Funds ownership: 3.29% → 8.65% (+5.4%)

0% more funds holding

Funds holding: 6 → 6 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$157K
2
VF
Virtu Financial
New York
+$9.75K
3
TRCT
Tower Research Capital (TRC)
New York
+$975

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$14.7K
2
TSS
Two Sigma Securities
New York
-$11.8K
3
UBS Group
UBS Group
Switzerland
-$139

DRMA Hedge Fund Activity: Q4 2023 in Review

6 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q4 2023, worth a combined $185K — up 68% from $110K a quarter earlier.

Fund positioning in DRMA was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $157K. The largest seller was Acadian Asset Management, cutting an estimated $14.7K.

  • 6 institutional investors held Dermata Therapeutics (DRMA) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $185K of Dermata Therapeutics stock for Q4 2023, up 68% quarter-over-quarter.
  • 2 funds opened new Dermata Therapeutics positions in Q4 2023 and 2 closed out, a net change of 0 holders.
  • The largest Dermata Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $157K added.
  • The largest Dermata Therapeutics seller in Q4 2023 was Acadian Asset Management, an estimated $14.7K sold.

Based on aggregated 13F filings for Q4 2023.